o Piperacillin-tazobactam (PTZ) is known to cause false-positive results in the Platelia Aspergillus enzyme-linked immunoassay (EIA), due to contamination with galactomannan (GM). We tested 32 lots of PTZ and 27 serum specimens from patients receiving PTZ. GM was not detected in the lots of PTZ; one serum specimen (3.7%) was positive. PTZ formulations commonly used in the United States today appear to be a rare cause for false-positive GM results.
arly diagnosis of invasive aspergillosis remains a challenge mainly due to its nonspecific clinical presentation and low sensitivity of fungal cultures from respiratory specimens. Galactomannan (GM), a heat-stable polysaccharide component of the cell walls of Aspergillus spp. and related molds, is released into the circulation system during invasive aspergillosis. The Platelia Aspergillus enzyme-linked immunoassay (EIA) detects a circulating GM antigen and is an important biomarker used for early nonculture diagnosis (1) (2) (3) .
False-positive Platelia Aspergillus EIA result attributed to treatment with piperacillin-tazobactam (PTZ) was first reported in 2003, and four lots of PTZ used in these patients contained GM (4). Piperacillin is produced as a fermentation product of molds of the genus Penicillium (5). Because Penicillium spp. contain GM in the cell wall, it has been hypothesized that GM may be carried through the PTZ production process (6) . It has been shown that older preparations of PTZ contain GM and cause false-positive results in patients (6, 7) . In an experimental model, GM was detected in the serum of rabbits receiving PTZ (8) .
Recent reports from Europe suggest that current formulations of PTZ no longer contain GM or cause false-positive results in the Platelia Aspergillus EIA (9, 10) . Based on the manufacturing process, GM content may differ based on brand and generic formulations prepared in different geographic areas. We sought to determine whether GM is present in lots of PTZ currently used in the United States and whether false-positive GM results still occur in patients receiving current preparations of PTZ.
Unopened vials of PTZ and premixed solutions for intravenous infusion (2.25, 3.375, and 4.5 g) were obtained from the pharmacies at the 12 participating institutions and stored in accordance with the manufacturer's instructions. The vials were reconstituted in accordance with the manufacturer's instructions. Serum specimens were obtained from patients at the Mayo Clinic who were receiving PTZ. The study was approved by the Institutional Review Board. Patients receiving PTZ for at least 5 days who were not at risk for or had no clinical or microbiologic evidence of invasive aspergillosis were included in the study. The patients were not receiving antifungal prophylaxis or treatment. A single specimen was collected from 25 study subjects. Two serum specimens (on different days) were collected from one study subject. Serum specimens were collected over a 4-week period (12 February through 13 March 2012) to ensure that patients receiving different lots of PTZ were included. Specimens were stored frozen at Ϫ20°C.
PTZ vials, the premixed solutions, and clinical specimens were shipped to MiraVista Diagnostics for testing in the Platelia Aspergillus EIA. PTZ and serum specimens were tested according to the Platelia Aspergillus EIA manufacturer's instructions (Bio-Rad, Redman, WA), except that the PTZ solutions were not heated and treated with EDTA. Results with a value of 0.5 ng/ml or higher were reported as positive. A total of 26 vials and six premixed solutions of PTZ from 14 collaborating institutions, representing 30 different lots from five different manufacturers, including 12 vials of the brand name product Zosyn, were tested in nine different test runs from 27 October 2011 to 8 February 2012 (Table 1) . GM was undetectable in all samples (range, 0.03 to 0.38; mean, 0.12; median, 0.11).
Twenty-seven serum specimens from patients receiving PTZ were tested in a single assay on 9 April 2012 (range, 0.07 to 3.31; mean, 0.22; median, 0.09). GM was detected in only one specimen (3.7%). The positive sample yielded a GM index of 3.3 when initially tested and 4.8 when repeated the following day. The specimen was negative for Histoplasma antigen. The patient was an 85-year-old woman with a history of chronic obstructive pulmonary disease, not receiving systemic corticosteroid treatment, who was admitted with respiratory failure requiring mechanical ventilation. Computed tomography (CT) imaging demonstrated pulmonary consolidations consistent with pneumonia. There was no bacterial or fungal growth in respiratory specimens. The patient was treated empirically with PTZ and vancomycin without clinical improvement and expired on hospital day 12. Autopsy showed pulmonary embolism and organizing pneumonia. No fungal organisms were identified by Giemsa staining lung tissue specimens. Cultures were not performed on the autopsy specimen. Although the premixed vials of PTZ that this patient received were not available for testing and the lot numbers were unknown, none of the six premixed solutions of PTZ tested from that institution contained GM.
Studies published on GM results and concurrent use of PTZ are summarized in Table 2 . Two non-U.S. studies suggested that PTZ no longer contains GM or causes false-positive results in patients treated with PTZ (9) . In a study of stem cell transplant recipients, 25 of 1,606 samples (1.6%) drawn in the absence of PTZ therapy were positive compared to 10 of 394 samples (2.5%) in patients receiving PTZ (P ϭ 0.18) (10) . Furthermore, 90 vials from 30 batches of PTZ tested negative for GM.
In a study among patients without risk factors for invasive aspergillosis, 135 serum samples were collected from 15 patients before and after PTZ (Wyeth Laboratories) infusion. Six serum samples (4.4%) were positive, 2 of which were obtained before the first dose of PTZ (9) . The GM indices for the positive specimens were Ͻ0.70.
A third study, however, found a higher positivity rate in patients receiving PTZ from one of three manufacturers. Results were positive in 17 of 34 (50%) patients receiving PTZ from Wyeth Laboratories from July 2009 to April 2010 compared to 13 of 53 (24.5%) who were not receiving PTZ (P ϭ 0.03). Of the four lots of PTZ that were tested, none were positive (11). Higher positivity was not observed from January 2009 to June 2009 using PTZ produced by Mylan Laboratory (35.0% positive receiving PTZ and 37.0% without PTZ) or from May 2010 to December 2010 using PTZ produced by Fresenius Laboratory (31.2% with PTZ and 29.3% without PTZ). Patients with proven/probable aspergillosis or histoplasmosis were not included in the analysis. The high rates of GM false-positive results in this study, including in patients not receiving PTZ, raises concerns about the validity of the reported association between PTZ and positive GM test. The positive test could be related to another source of GM, including other invasive fungal infections or other cross-reacting medication.
Our results extend and corroborate previous studies indicating that both generic and brand name PTZ products no longer contain GM. It is now unlikely that administration of PTZ will result in a false-positive result for the Platelia Aspergillus EIA.
